[go: up one dir, main page]

PE20081753A1 - Compuestos y composiciones como inhibidores de la proteasa activadora de canal - Google Patents

Compuestos y composiciones como inhibidores de la proteasa activadora de canal

Info

Publication number
PE20081753A1
PE20081753A1 PE2008000284A PE2008000284A PE20081753A1 PE 20081753 A1 PE20081753 A1 PE 20081753A1 PE 2008000284 A PE2008000284 A PE 2008000284A PE 2008000284 A PE2008000284 A PE 2008000284A PE 20081753 A1 PE20081753 A1 PE 20081753A1
Authority
PE
Peru
Prior art keywords
alkyl
compounds
inhibitors
compositions
activating protease
Prior art date
Application number
PE2008000284A
Other languages
English (en)
Inventor
David C Tully
Arnab K Chatterjee
Agnes Vidal
Badry Bursulaya
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39322557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081753(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20081753A1 publication Critical patent/PE20081753A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE B ES DE PREFERENCIA 3-(4-PIPERIDINIL)-1N-METILSULFONILAMIDA; Y ES -SO2-, -NHCO-, -CO-, ENTRE OTROS; J ES BENZOXAZOLILO, 1,2,3-OXADIAZOL-2-ILO, OXAZOLO-[4,5-b]-PIRIDIN-2-ILO, ENTRE OTROS; R1 ES H, ALQUILO C1-C6, OPCIONALMENTE HALOGENADO, ALQUENILO C2-C6, ENTRE OTROS; R2 ES ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R3 ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R4 ES ALQUILO C1-C6, ALQUENILO C2-C6, ANILLO HETEROCICLICO, ENTRE OTROS; R5 ES ANILLO CARBOCICLICO DE 5-12 MIEMBROS OPCIONALMENTE SUSTITUIDO, ANILLO HETEROCICLICO, ENTRE OTROS; k, m Y n SON CADA UNO 1-6. SON COMPUESTOS PREFERIDOS: A, B, ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEASA ACTIVADORA DE CANAL (CAP) UTILES EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
PE2008000284A 2007-02-09 2008-02-08 Compuestos y composiciones como inhibidores de la proteasa activadora de canal PE20081753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88900807P 2007-02-09 2007-02-09

Publications (1)

Publication Number Publication Date
PE20081753A1 true PE20081753A1 (es) 2009-01-22

Family

ID=39322557

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000284A PE20081753A1 (es) 2007-02-09 2008-02-08 Compuestos y composiciones como inhibidores de la proteasa activadora de canal

Country Status (14)

Country Link
US (1) US20100239551A1 (es)
EP (1) EP2117541A1 (es)
JP (1) JP2010518097A (es)
CN (1) CN101646437A (es)
AR (1) AR065266A1 (es)
AU (1) AU2008214214B2 (es)
BR (1) BRPI0806970A2 (es)
CA (1) CA2677485A1 (es)
CL (1) CL2008000408A1 (es)
EA (1) EA200901082A1 (es)
MX (1) MX2009008493A (es)
PE (1) PE20081753A1 (es)
TW (1) TW200845982A (es)
WO (1) WO2008097673A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
RU2419626C2 (ru) 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
CA2677487A1 (en) * 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
EP2320886B1 (en) 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
KR101687039B1 (ko) 2008-10-03 2016-12-15 젠자임 코포레이션 2-아실아미노프로판올형 글루코실세라미드 합성효소 억제제
AR076880A1 (es) 2009-05-18 2011-07-13 Orion Corp Inhibidores de proteasa, composiciones farmaceuticas que los contienen y su uso.
DE102009022794A1 (de) * 2009-05-27 2010-12-02 Philipps-Universität Marburg Verwendung von Hemmstoffen der HAT und TMPRSS2 als Arzneimittel
US8729061B2 (en) * 2011-11-25 2014-05-20 Hoffmann-La Roche Inc. Pyrrolidine derivatives
NZ704666A (en) 2012-08-23 2018-05-25 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
HRP20181197T1 (hr) * 2013-10-29 2018-11-30 Biomarin Pharmaceutical Inc. Derivati n-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamida kao inhibitori glukozilceramid sintaze
CN107153117B (zh) * 2016-03-04 2019-02-19 中国人民解放军军事医学科学院生物工程研究所 一种用于判断靶向单克隆抗体治疗肿瘤疗效的预测分子

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
US6150334A (en) * 1994-11-21 2000-11-21 Cortech, Inc. Serine protease inhibitors-tripeptoid analogs
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5523308A (en) * 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
TW523513B (en) * 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
EP1114822A3 (en) * 1998-06-03 2002-11-13 Cortech Inc. Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors
KR20010078724A (ko) * 1998-06-03 2001-08-21 존 더블류. 갈루치 2세 세린 프로테아제 저해제로서의 인돌 및테트라히드로이소퀴놀린을 함유하는 α-케토 옥사디아졸
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
EP1147097A1 (en) * 1999-01-27 2001-10-24 Ortho-Mcneil Pharmaceutical, Inc. Peptidyl heterocyclic ketones useful as tryptase inhibitors
JP2000256396A (ja) * 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
JP2003533448A (ja) 2000-04-27 2003-11-11 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規持続性ベータ擬似剤、その製造方法及びその医薬としての使用
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
ES2523930T3 (es) 2000-08-05 2014-12-02 Glaxo Group Limited Éster s-fluorometílico del ácido 6-alfa,9-alfa-difluoro-17-alfa-[(2-furanilcarbonil)oxi]-11-beta-hidroxi-16-alfa-metil-3-oxo-androst-1,4-dien-17-carbotioico como agente antiinflamatorio
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2288543T3 (es) 2001-03-08 2008-01-16 Glaxo Group Limited Agonistas de beta-adrenorreceptores.
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
PT1383786E (pt) 2001-04-30 2008-12-30 Glaxo Group Ltd Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa
US20040248867A1 (en) 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
DK1425001T3 (da) 2001-09-14 2009-04-14 Glaxo Group Ltd Phenethanolaminderivater til behandling af respiratoriske sygdomme
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
ATE392206T1 (de) 2002-10-11 2008-05-15 Pfizer Indolderivate als beta-2 agonisten
PL2019837T3 (pl) * 2006-05-23 2011-09-30 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywującej kanały
RU2419626C2 (ru) * 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы

Also Published As

Publication number Publication date
CA2677485A1 (en) 2008-08-14
EP2117541A1 (en) 2009-11-18
AU2008214214A1 (en) 2008-08-14
TW200845982A (en) 2008-12-01
AR065266A1 (es) 2009-05-27
BRPI0806970A2 (pt) 2014-04-08
AU2008214214B2 (en) 2011-09-15
WO2008097673A1 (en) 2008-08-14
JP2010518097A (ja) 2010-05-27
CN101646437A (zh) 2010-02-10
EA200901082A1 (ru) 2010-02-26
CL2008000408A1 (es) 2008-08-29
US20100239551A1 (en) 2010-09-23
MX2009008493A (es) 2009-08-20

Similar Documents

Publication Publication Date Title
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20090772A1 (es) Derivados de bencimidazol
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20141907A1 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20141120A1 (es) Compuestos heterociclicos
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20090641A1 (es) Amidas heterociclicas
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20060241A1 (es) 2-quinolil-oxazoles sustituidos como inhibidores de pde4
PE20120632A1 (es) Inhibidores de bace
PE20091810A1 (es) Pirimidin-5-carboxamidas sustituidas 281
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20140011A1 (es) Compuestos y composiciones novedosos para la inhibicion de nampt
PE20091841A1 (es) Inhibidores del virus de hepatitis c
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20080409A1 (es) Compuestos que modulan en el receptor cb2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal